Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.
Kenai Therapeutics has raised $82.0M in total funding. The most recent round was Series A. The last funding was announced in February 2024.
Kenai Therapeutics's investors include The Column Group, Cure Ventures, Alaska Permanent Fund, California Institute for Regenerative Medicine, Saisei Ventures.
Kenai Therapeutics is headquartered in San Diego, United States.
Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.
Kenai Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kenai Therapeutics — Funding & Investors." VCBacked, February 29, 2024, https://www.vcbacked.co/company/kenai-therapeutics. Accessed July 27, 2026.
VCBacked. (2024). Kenai Therapeutics — Funding & Investors. Retrieved July 27, 2026, from https://www.vcbacked.co/company/kenai-therapeutics
{{cite web |title=Kenai Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kenai-therapeutics |website=VCBacked |access-date=July 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated